Zebrafish in understanding molecular pathophysiology, disease modeling, and developing effective treatments for Rett syndrome
The Journal of Gene Medicine · 2024-02 · 26 (2)
DOI: 10.1002/jgm.3677 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Gene Medicine, online erschienen am 21.02.2024. Verfasst von Subrata Pramanik und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jyoti and Bhupat Mehta School of Health Sciences and Technology, Indian Institute of Technology Guwahati, Guwahati, Assam, India. Hauptthemen laut MEDLINE: Rett Syndrome, Intellectual Disability. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: ICMR Center for Excellence, SERB Start-up Research Grant (SRG), Indian Institute of Technology Guwahati, INUP-MeitY.
Abstract (Originalsprache)
Rett syndrome (RTT) is a rare but dreadful X‐linked genetic disease that mainly affects young girls. It is a neurological disease that affects nerve cell development and function, resulting in severe motor and intellectual disabilities. To date, no cure is available for treating this disease. In 90% of the cases, RTT is caused by a mutation in methyl‐CpG‐binding protein 2 (MECP2), a transcription factor involved in the repression and activation of transcription. MECP2 is known to regulate several target genes and is involved in different physiological functions. Mouse models exhibit a broad range of phenotypes in recapitulating human RTT symptoms; however, understanding the disease mechanisms remains incomplete, and many potential RTT treatments developed in mouse models have not shown translational effectiveness in human trials. Recent data hint that the zebrafish model emulates similar disrupted neurological functions following mutation of the mecp2 gene. This suggests that zebrafish can be used to understand the onset and progression of RTT pathophysiology and develop a possible cure. In this review, we elaborate on the molecular basis of RTT pathophysiology in humans and model organisms, including rodents and zebrafish, focusing on the zebrafish model to understand the molecular pathophysiology and the development of therapeutic strategies for RTT. Finally, we propose a rational treatment strategy, including antisense oligonucleotides, small interfering RNA technology and induced pluripotent stem cell‐derived cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jyoti and Bhupat Mehta School of Health Sciences and Technology, Indian Institute of Technology Guwahati, Guwahati, Assam, India.
- Centre for Nanotechnology, Indian Institute of Technology Guwahati, Guwahati, Assam, India.
- Pharmacology and Drug Discovery Research Laboratory, Division of Life Sciences; Institute of Advanced Study in Science and Technology (IASST), An Autonomous Institute Under - Department of Science & Technology (Govt. of…
- Biology, The Life Science Center, School of Science and Technology, Örebro University, Örebro, Sweden.
ORCID-Profile: Subrata Pramanik
Förderung
- ICMR Center for Excellence
- SERB Start-up Research Grant (SRG)
- Indian Institute of Technology Guwahati, INUP-MeitY
- Örebro University, Sweden
Zitieren
APA
Pramanik, S., Bala, A., & Pradhan, A. (2024). Zebrafish in understanding molecular pathophysiology, disease modeling, and developing effective treatments for Rett syndrome. The Journal of Gene Medicine, 26(2). https://doi.org/10.1002/jgm.3677
Vancouver
Pramanik S, Bala A, Pradhan A. Zebrafish in understanding molecular pathophysiology, disease modeling, and developing effective treatments for Rett syndrome. The Journal of Gene Medicine. 2024;26(2). doi:10.1002/jgm.3677
BibTeX
@article{Pramanik2024,
author = {Pramanik, Subrata and Bala, Asis and Pradhan, Ajay},
title = {Zebrafish in understanding molecular pathophysiology, disease modeling, and developing effective treatments for Rett syndrome},
journal = {The Journal of Gene Medicine},
year = {2024},
volume = {26},
number = {2},
doi = {10.1002/jgm.3677}
}
EUVIMED